NCT07176260Recruiting
Exploring Blood Cell Function and Oxidative Stress to Improve Diagnosis and Treatment in Pre-Capillary Pulmonary Hypertension
Diagnostic and Prognostic Significance of Circulating Oxidative Stress and Blood Cell Mitochondrial Respiration in Pre-Capillary Pulmonary Hypertension
Source: ClinicalTrials.gov · Last updated 16 Sept 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This study aims to understand how blood cell (including peripheral blood mononuclear cells ((PBMCs) or platelets) function and oxidative stress can help physicians detect and predict the course of pre-capillary pulmonary hypertension. We hypothesize that changes in the mitochondrial function of blood cells and oxidative stress may be early markers of disease progression and severity. The study will also explore how these blood markers relate to routine clinical and heart function measurements, such as echocardiography, right heart catheterization, 6-minute walk tests, and functional status, to see if they can help monitor patients over time and guide personalized care. This is a non-interventional study. Blood samples will be collected during routine visits planned for diagnosis and follow-up. The study will include 120 patients diagnosed with pre-capillary pulmonary hypertension, who will be followed for 3 years. Blood samples will be taken up to three times per year to measure mainly oxidative stress and mitochondrial function in blood cells. These measurements will be compared with clinical tests to see if they can help predict the course of the disease.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 120 (estimated)
- First submitted
- 8 Sept 2025
- Start date
- Sept 2025
- Primary completion date
- Sept 2025
- Lead sponsor
- University Hospital, Strasbourg, France
- NCT number
- NCT07176260
What you commit to
- Study type: Observational
- Planned participants: 120
- From Sept 2025 to the primary completion date, Sept 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Postcapillary pulmonary hypertension (pulmonary arterial wedge pressure \>15 mmHg).
- Conditions precluding safe blood sampling (e.g., severe anemia, coagulopathy).
Other
- Patients already enrolled in interventional clinical trials that could interfere with mitochondrial or oxidative stress measurements
- Patients unable or unwilling to provide informed consent
- Pregnancy or breastfeeding
Who the study is looking for
- Adult patients (≥18 years) diagnosed with pre-capillary pulmonary hypertension confirmed by right heart catheterization
- Patients classified according to the international clinical classification:
- Group 1: Pulmonary arterial hypertension (PAH)
- Group 3: Pulmonary hypertension associated with chronic respiratory diseases and/or hypoxia
- Group 4: Chronic thromboembolic pulmonary hypertension (CTEPH)
- Patients scheduled for routine clinical follow-up and/or right heart catheterization at the study center.
- Ability and willingness to provide informed consent for participation and data analysis.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hôpitaux Universitaires de Strasbourg - Service Physiologie explorations fonctionnelles Coordinator of this site? Confirm its status | Strasbourg | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.